Ajinomoto Bio-Pharma Rebrands to Highlight Specialized CDMO Expertise

The rebranding effort centers on the company’s focus across diverse modalities, including small molecules, oligonucleotides, peptides, gene therapy, proteins, and bioconjugates. By highlighting this technical depth, the firm intends to differentiate itself as a provider capable of solving precise manufacturing hurdles rather than offering generalized services. This strategic shift draws heavily on the Ajinomoto Group’s century-long history of scientific research and proprietary technology development.

"Our new brand puts that strength at the center," said Yasuyuki Otake, General Manager of the Bio-Pharma Services Department at Ajinomoto Co. "It reflects the ingenuity of our teams around the world and our commitment to helping customers unlock innovation." The updated identity is currently live on the company’s website and social channels, with a broader rollout of marketing materials planned for upcoming industry conferences. The organization maintains a global footprint with manufacturing sites located in Japan, the United States, Belgium, and India.